We develop and produce highly specialized targeted investor and business development conferences exclusively for the biopharmaceutical and life sciences industries.
With over 20 years’ experience connecting leaders of innovative biotech companies with key stakeholders, investors and advisors, we create ideal environments to examine and address opportunities and challenges in today’s biotech industry.
Get to know us, a respected leader in biotech investor conferences and highly targeted leadership events.
Who we are ⇢
See how we create communities that foster lasting and mutually beneficial relationships.
What we do ⇢
How innovation is shaping the biopharmaceutical industry.
What we think ⇢
The greatest ideas and innovations are those that fill a large gap in a field. And Biotech Showcase (BTS) was created for just such a purpose. There are hundreds, if not thousands, of biotech companies that are not ready for financing with the bulge bracket players – the largest and most recognized banks – like JPMorgan. Yet, they are ready to present their work and show investors how they have been hitting marks and building profiles. Thus, the creation of BTS. A place where small and mid-sized (and growing into larger) biotech companies can present, meet potential investors and partners, and know that the event organizers are on their side. And more importantly, fill that gap in the biotech space by helping those smaller companies get where they need to be.
The year ahead in biotech is primed to be a stock-pickers' market. Fundamental growth among commercial biotechs in the U.S. is forecast to be similar to 2017, while non-U.S. stocks are poised for a slowdown. In this regard, Gilead is set for another challenging year, while Amgen and Vertex could surprise on commercial execution. The top potential clinical catalyst plays across BI's coverage include Celgene, Biogen, Incyte and Exelixis.
In the big picture, political threats to drug pricing may be reignited after a subdued 2017. Payer-driven pressure is expected to remain opportunistically rampant and pressure recent launches. It's unclear if 2018 will wake up M&A after a sleepy 2017, but licensing deals should carry on strong.
